312 related articles for article (PubMed ID: 27091202)
1. C-reactive protein as a prognostic factor in patients with chordoma of lumbar spine and sacrum--a single center pilot study.
Hobusch GM; Bodner F; Walzer S; Marculescu R; Funovics PT; Sulzbacher I; Windhager R; Panotopoulos J
World J Surg Oncol; 2016 Apr; 14():111. PubMed ID: 27091202
[TBL] [Abstract][Full Text] [Related]
2. Chordoma of the mobile spine and sacrum: a retrospective analysis of a series of patients surgically treated at two referral centers.
Stacchiotti S; Casali PG; Lo Vullo S; Mariani L; Palassini E; Mercuri M; Alberghini M; Pilotti S; Zanella L; Gronchi A; Picci P
Ann Surg Oncol; 2010 Jan; 17(1):211-9. PubMed ID: 19847568
[TBL] [Abstract][Full Text] [Related]
3. Prognostic factors in chordoma of the sacrum and mobile spine: a study of 39 patients.
Bergh P; Kindblom LG; Gunterberg B; Remotti F; Ryd W; Meis-Kindblom JM
Cancer; 2000 May; 88(9):2122-34. PubMed ID: 10813725
[TBL] [Abstract][Full Text] [Related]
4. What Are the Conditional Survival and Functional Outcomes After Surgical Treatment of 115 Patients With Sacral Chordoma?
Ji T; Guo W; Yang R; Tang X; Wang Y; Huang L
Clin Orthop Relat Res; 2017 Mar; 475(3):620-630. PubMed ID: 26975382
[TBL] [Abstract][Full Text] [Related]
5. Prognostic factors in surgical resection of sacral chordoma.
Angelini A; Pala E; Calabrò T; Maraldi M; Ruggieri P
J Surg Oncol; 2015 Sep; 112(4):344-51. PubMed ID: 26238085
[TBL] [Abstract][Full Text] [Related]
6. Mobile spine chordoma: results of 166 patients from the AOSpine Knowledge Forum Tumor database.
Gokaslan ZL; Zadnik PL; Sciubba DM; Germscheid N; Goodwin CR; Wolinsky JP; Bettegowda C; Groves ML; Luzzati A; Rhines LD; Fisher CG; Varga PP; Dekutoski MB; Clarke MJ; Fehlings MG; Quraishi NA; Chou D; Reynolds JJ; Williams RP; Kawahara N; Boriani S
J Neurosurg Spine; 2016 Apr; 24(4):644-51. PubMed ID: 26682601
[TBL] [Abstract][Full Text] [Related]
7. Surgical treatment of sacral chordoma: survival and prognostic factors.
Ruosi C; Colella G; Di Donato SL; Granata F; Di Salvatore MG; Fazioli F
Eur Spine J; 2015 Nov; 24 Suppl 7():912-7. PubMed ID: 26458933
[TBL] [Abstract][Full Text] [Related]
8. Recurrence and survival factors analysis of 171 cases of sacral chordoma in a single institute.
Yang Y; Niu X; Li Y; Liu W; Xu H
Eur Spine J; 2017 Jul; 26(7):1910-1916. PubMed ID: 27942938
[TBL] [Abstract][Full Text] [Related]
9. Expression of vascular endothelial growth factor and matrix metalloproteinase-9 in sacral chordoma.
Chen KW; Yang HL; Lu J; Wang GL; Ji YM; Wu GZ; Zhu LF; Liu JY; Chen XQ; Gu YP
J Neurooncol; 2011 Feb; 101(3):357-63. PubMed ID: 20549300
[TBL] [Abstract][Full Text] [Related]
10. The impact of radiotherapy on survival after surgical resection of chordoma with minimum five-year follow-up.
Tobert DG; Kelly SP; Xiong GX; Chen YL; MacDonald SM; Bongers ME; Lozano-Calderon SA; Newman ET; Raskin KA; Schwab JH
Spine J; 2023 Jan; 23(1):34-41. PubMed ID: 35470086
[TBL] [Abstract][Full Text] [Related]
11. Long-term clinical outcomes following en bloc resections for sacral chordomas and chondrosarcomas: a series of twenty consecutive patients.
Hsieh PC; Xu R; Sciubba DM; McGirt MJ; Nelson C; Witham TF; Wolinksy JP; Gokaslan ZL
Spine (Phila Pa 1976); 2009 Sep; 34(20):2233-9. PubMed ID: 19752710
[TBL] [Abstract][Full Text] [Related]
12. Sacral chordoma: a clinical review of 101 cases with 30-year experience in a single institution.
van Wulfften Palthe ODR; Tromp I; Ferreira A; Fiore A; Bramer JAM; van Dijk NC; DeLaney TF; Schwab JH; Hornicek FJ
Spine J; 2019 May; 19(5):869-879. PubMed ID: 30445184
[TBL] [Abstract][Full Text] [Related]
13. High expression of survivin in sacral chordoma.
Chen C; Yang HL; Chen KW; Wang GL; Lu J; Yuan Q; Gu YP; Luo ZP
Med Oncol; 2013 Jun; 30(2):529. PubMed ID: 23504337
[TBL] [Abstract][Full Text] [Related]
14. Oncologic and functional outcome following sacrectomy for sacral chordoma.
Hulen CA; Temple HT; Fox WP; Sama AA; Green BA; Eismont FJ
J Bone Joint Surg Am; 2006 Jul; 88(7):1532-9. PubMed ID: 16818979
[TBL] [Abstract][Full Text] [Related]
15. Overexpression of Raf-1 and ERK1/2 in sacral chordoma and association with tumor recurrence.
Zhang K; Chen H; Zhang B; Sun J; Lu J; Chen K; Yang H
Int J Clin Exp Pathol; 2015; 8(1):608-14. PubMed ID: 25755752
[TBL] [Abstract][Full Text] [Related]
16. Survival of patients with malignant primary osseous spinal neoplasms: results from the Surveillance, Epidemiology, and End Results (SEER) database from 1973 to 2003.
Mukherjee D; Chaichana KL; Gokaslan ZL; Aaronson O; Cheng JS; McGirt MJ
J Neurosurg Spine; 2011 Feb; 14(2):143-50. PubMed ID: 21184634
[TBL] [Abstract][Full Text] [Related]
17. Late local recurrence, at 19 and 17 years, of sacral chordoma treated by en bloc resection.
Dubory A; Missenard G; Court C
Orthop Traumatol Surg Res; 2016 Feb; 102(1):121-5. PubMed ID: 26796999
[TBL] [Abstract][Full Text] [Related]
18. Sacral chordoma: do the width of surgical margin and the use of photon/proton radiotherapy affect local disease control?
Fujiwara T; Tsuda Y; Stevenson J; Parry M; Jeys L
Int Orthop; 2020 Feb; 44(2):381-389. PubMed ID: 31863159
[TBL] [Abstract][Full Text] [Related]
19. Analysis of risk factors for recurrence after the resection of sacral chordoma combined with embolization.
Yang H; Zhu L; Ebraheim NA; Liu X; Castillo S; Tang T; Liu J; Cui H
Spine J; 2009 Dec; 9(12):972-80. PubMed ID: 19800296
[TBL] [Abstract][Full Text] [Related]
20. Chordoma: long-term evaluation of 15 cases treated surgically.
Logroscino CA; Astolfi S; Sacchettoni G
Chir Organi Mov; 1998; 83(1-2):87-103. PubMed ID: 9718818
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
